Price T Rowe Associates Inc. MD Has $160,000 Stock Holdings in Bioventus Inc. (NYSE:BVS)

Price T Rowe Associates Inc. MD grew its holdings in Bioventus Inc. (NYSE:BVS) by 26.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,194 shares of the company’s stock after buying an additional 3,153 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Bioventus were worth $160,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in BVS. Tower Research Capital LLC TRC grew its holdings in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after purchasing an additional 1,786 shares during the last quarter. Plato Investment Management Ltd bought a new stake in shares of Bioventus in the 4th quarter worth about $38,000. KLP Kapitalforvaltning AS bought a new stake in shares of Bioventus in the 4th quarter worth about $75,000. Quantbot Technologies LP bought a new stake in shares of Bioventus in the 4th quarter worth about $103,000. Finally, Arizona State Retirement System bought a new stake in shares of Bioventus in the 4th quarter worth about $109,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Craig Hallum set a $15.00 target price on shares of Bioventus and gave the stock a “buy” rating in a report on Wednesday, May 7th. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th.

Bioventus Stock Up 3.8%

Shares of NYSE:BVS opened at $6.79 on Friday. Bioventus Inc. has a 12 month low of $5.28 and a 12 month high of $14.38. The company’s 50-day moving average price is $8.09 and its two-hundred day moving average price is $9.84. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The firm has a market cap of $556.40 million, a P/E ratio of -11.13 and a beta of 0.95.

Insiders Place Their Bets

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the firm’s stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the transaction, the chief financial officer now owns 141,088 shares of the company’s stock, valued at approximately $1,068,036.16. This trade represents a 2.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Anthony D’adamio sold 4,380 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. This trade represents a 3.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,208 shares of company stock valued at $226,138 in the last 90 days. 32.90% of the stock is currently owned by insiders.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.